Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody that is used to treat plaque...
11 KB (668 words) - 04:42, 6 July 2024
Intracellular (reception) Extracellular Unsorted Avacopan Baricitinib Bimekizumab Blisibimod Briakinumab Brodalumab Canakinumab Crovalimab Danicopan Darvadstrocel...
7 KB (299 words) - 13:45, 27 April 2024
Kremers, filed for Chapter 11 bankruptcy. Atarax (hydroxyzine) Bimzelx (bimekizumab) Briviact (Brivaracetam) Nootropil (piracetam) Zyrtec (cetirizine), an...
13 KB (1,216 words) - 21:03, 1 March 2024
Secukinumab Sirukumab Tralokinumab Ustekinumab Humanized Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab† Lebrikizumab Olokizumab†...
38 KB (4,304 words) - 20:57, 1 December 2023
L04AC18 Risankizumab L04AC19 Satralizumab L04AC20 Netakimab L04AC21 Bimekizumab L04AC22 Spesolimab L04AC23 Olokizumab L04AD01 Ciclosporin L04AD02 Tacrolimus...
3 KB (367 words) - 15:37, 25 January 2024
immune tolerance. There is strong evidence to indicate that infliximab, bimekizumab, ixekizumab, and risankizumab are the most effective biologics for treating...
115 KB (12,976 words) - 19:15, 18 June 2024
thromboembolism (diagnosis) Bimagrumab mab human ACVR2B myostatin inhibitor Bimekizumab Bimzelx mab humanized IL-17A, IL-17F, IL-17AF Y psoriasis Birtamimab...
135 KB (4,054 words) - 22:35, 2 July 2024
Secukinumab Sirukumab Tralokinumab Ustekinumab Humanized Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab† Lebrikizumab Olokizumab†...
2 KB (87 words) - 01:28, 30 May 2023
McInnes". "AAD Reading Room | Iain McInnes, MD, on the Latest Findings on Bimekizumab for Psoriatic Arthritis | MedPage Today". "EULAR Message from the President...
17 KB (1,378 words) - 04:02, 6 July 2024
Intracellular (reception) Extracellular Unsorted Avacopan Baricitinib Bimekizumab Blisibimod Briakinumab Brodalumab Canakinumab Crovalimab Danicopan Darvadstrocel...
38 KB (2,656 words) - 12:11, 30 October 2023
inhibit the synthesis of new cartilage matrix. The monoclonal antibody bimekizumab against IL-17A and IL-17F is approved in Europe for the treatment of...
10 KB (1,309 words) - 03:03, 22 May 2024